| 33.23 1.16 (3.62%) | 11-11 15:56 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 38.67 |
1-year : | 45.16 |
| Resists | First : | 33.11 |
Second : | 38.67 |
| Pivot price | 30.63 |
|||
| Supports | First : | 26.99 |
Second : | 23.2 |
| MAs | MA(5) : | 31.82 |
MA(20) : | 30.28 |
| MA(100) : | 23.68 |
MA(250) : | 17.6 |
|
| MACD | MACD : | 1.5 |
Signal : | 1.5 |
| %K %D | K(14,3) : | 84.3 |
D(3) : | 81.2 |
| RSI | RSI(14): 67.2 |
|||
| 52-week | High : | 33.11 | Low : | 7.75 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ASMB ] has closed below upper band by 15.7%. Bollinger Bands are 8.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 32.38 - 32.54 | 32.54 - 32.7 |
| Low: | 31.13 - 31.29 | 31.29 - 31.46 |
| Close: | 31.8 - 32.07 | 32.07 - 32.33 |
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Mon, 10 Nov 2025
Assembly Biosciences Inc. Reports Q3 2025 Earnings - TipRanks
Mon, 10 Nov 2025
Assembly Bio (ASMB) Exceeds Q3 Revenue Expectations with Notable Pipeline Progress - GuruFocus
Mon, 10 Nov 2025
Assembly Biosciences: Q3 Earnings Snapshot - San Francisco Chronicle
Mon, 10 Nov 2025
Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates - The Manila Times
Fri, 07 Nov 2025
Assembly Biosciences (ASMB) Unveils Promising Phase 1b Data for Hepatitis B Treatment - GuruFocus
Fri, 07 Nov 2025
Assembly Bio (NASDAQ: ASMB) Phase 1b ABI-4334: multi-log HBV DNA declines, well tolerated - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 16 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 38.5 (%) |
| Held by Institutions | 25.6 (%) |
| Shares Short | 1,530 (K) |
| Shares Short P.Month | 1,070 (K) |
| EPS | -5.56 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.35 |
| Profit Margin | -117.2 % |
| Operating Margin | -115.3 % |
| Return on Assets (ttm) | -27.8 % |
| Return on Equity (ttm) | -147.7 % |
| Qtrly Rev. Growth | 12.8 % |
| Gross Profit (p.s.) | -1.65 |
| Sales Per Share | 2.13 |
| EBITDA (p.s.) | -2.79 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -56 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -5.86 |
| PEG Ratio | 0 |
| Price to Book value | 13.78 |
| Price to Sales | 15.22 |
| Price to Cash Flow | -9.07 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|